A Phase I/II Study of Bavituximab and Sorafenib In Patients With Advanced Hepatocellular Carcinoma.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 07 May 2018
At a glance
- Drugs Bavituximab (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 31 May 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016.
- 31 May 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016.
- 02 Jun 2015 Results (n=38) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.